The recent Science and Technology Forum, with more than 40 presentations, clearly shows the potential of the institution, whose flagship products include Gavac, an immunogen against the Rhipicephalus (Boophilus) microplus tick in cattle.
Camagüey CIGB Director Nemecio Gonzalez Fernandez told Cadena Agramonte that “the research responds to the agriculture program, energy saving and efficiency, manufacture and recovery of spare parts and reduce imports.”
In early 2022, the institution achieved a production record of the PORVAC vaccine against classic swine fever, since it obtained 1,900,000 doses for the first time.
New scientific collaboration agreements mark the path of innovation and science between the University of Camagüey (UC), the Cuban Biocubafarma Company and the local CIGB branch.
The international recognition of the teaching staff and the various research fields have strengthened the bond between both institutions that have as a special mediator the Center for Genetic Engineering and Biotechnology (CIGB) in Camagüey.